IRIS PubliCatt

Patrono, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.480
EU - Europa 2.390
AS - Asia 1.107
SA - Sud America 44
OC - Oceania 21
AF - Africa 20
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.064
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.461
CN - Cina 580
DE - Germania 549
SE - Svezia 485
IT - Italia 374
UA - Ucraina 321
SG - Singapore 226
IE - Irlanda 188
FR - Francia 114
GB - Regno Unito 114
ID - Indonesia 113
FI - Finlandia 77
RU - Federazione Russa 68
IN - India 50
TR - Turchia 28
BE - Belgio 17
BR - Brasile 16
CA - Canada 16
IR - Iran 16
KR - Corea 15
AU - Australia 13
CH - Svizzera 13
ES - Italia 13
HK - Hong Kong 13
CL - Cile 12
PH - Filippine 12
NL - Olanda 11
TH - Thailandia 9
CI - Costa d'Avorio 8
NZ - Nuova Zelanda 8
PK - Pakistan 8
AT - Austria 7
CZ - Repubblica Ceca 7
PL - Polonia 7
VN - Vietnam 7
EG - Egitto 6
AR - Argentina 5
JP - Giappone 5
PE - Perù 5
RO - Romania 5
IL - Israele 4
IQ - Iraq 4
DZ - Algeria 3
MK - Macedonia 3
NO - Norvegia 3
VE - Venezuela 3
A1 - Anonimo 2
BH - Bahrain 2
CO - Colombia 2
GE - Georgia 2
KW - Kuwait 2
KZ - Kazakistan 2
LI - Liechtenstein 2
MD - Moldavia 2
MY - Malesia 2
NP - Nepal 2
PT - Portogallo 2
BD - Bangladesh 1
BG - Bulgaria 1
CM - Camerun 1
CR - Costa Rica 1
EC - Ecuador 1
GR - Grecia 1
HU - Ungheria 1
KE - Kenya 1
LT - Lituania 1
LV - Lettonia 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
MX - Messico 1
SA - Arabia Saudita 1
SD - Sudan 1
SI - Slovenia 1
SV - El Salvador 1
TJ - Tagikistan 1
TW - Taiwan 1
Totale 6.064
Salva come PNG Salva come JPEG
Città #
Chandler 408
Ashburn 232
Jacksonville 184
Dublin 174
San Mateo 156
Singapore 149
Nanjing 133
Jakarta 112
Hangzhou 102
Wilmington 94
Beijing 92
Cattolica 87
Woodbridge 81
Ann Arbor 70
Boston 68
Lawrence 63
Rome 52
Menlo Park 50
Moscow 50
Houston 48
Milan 45
Redwood City 45
Nanchang 41
Dearborn 39
Fairfield 36
Princeton 35
Seattle 29
Bremen 26
Mountain View 26
Redmond 26
Chicago 24
Shenyang 24
New York 23
Hebei 22
Kunming 22
Boardman 21
Izmir 20
Lancaster 20
Bareggio 17
Brussels 17
Los Angeles 17
Tianjin 16
University Park 12
Jiaxing 11
Leawood 11
Norwalk 11
Nürnberg 11
Augusta 10
Guangzhou 10
Hounslow 10
London 10
Munich 10
Abidjan 8
Detroit 8
Helsinki 8
Hong Kong 8
Philadelphia 8
Pune 8
Shanghai 8
Washington 8
Edinburgh 7
Lanzhou 7
Quezon City 7
Changsha 6
Vimercate 6
Andover 5
Busto Arsizio 5
Catania 5
Changchun 5
Marseille 5
Ottawa 5
Paris 5
Ankara 4
Bangkok 4
Brno 4
Chieti 4
Florence 4
Frankfurt am Main 4
Garanhuns 4
Hefei 4
Indiana 4
Jinan 4
Karlsruhe 4
Kish 4
Latham 4
Lima 4
Münster 4
Salò 4
Santiago 4
Uster 4
Vienna 4
Aberdeen 3
Auckland 3
Avon 3
Cambridge 3
Coleraine 3
Falls Church 3
Groningen 3
Henderson 3
Islamabad 3
Totale 3.337
Salva come PNG Salva come JPEG
Nome #
Antiplatelet agents for the treatment and prevention of atherothrombosis 162
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 145
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes 134
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 122
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus 121
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 118
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 112
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 111
Aspirin Continues to Attract Research and Debate, 115 Years After Its Synthesis 110
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes 106
Nutraceuticals in diabetes and metabolic syndrome. 101
Increased thromboxane biosynthesis in essential thrombocythemia. 97
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) 92
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 88
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. 87
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 85
Drug insight: aspirin resistance- fact or fashion 84
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 84
Platelet activation and atherothrombosis 83
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 81
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 79
Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective 78
Type 2 Diabetes, Obesity, and Aspirin Responsiveness* 78
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells 76
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia 75
Aspirin: promise and resistance in the new millennium. 74
Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C →T polymorphism 74
The future of antiplatelet therapy in cardiovascular disease 73
Antiplatelet therapy:aspirin for asymptomatic atherosclerosis? 72
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 72
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 71
Non-steroidal anti-inflammatory drugs 70
Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment 68
Low-dose aspirin for the prevention of atherothrombosis 68
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) 67
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy 66
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials 65
Aspirin 65
Platelet progenitors: the hidden drug target 65
Low-Dose Aspirin, Coxibs, and other NSAIDS: A clinical Mosaic Emerges. 63
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 63
Determinants of platelet activation in Alzheimer's disease. 62
Aspirin 62
Eicosanoid biosynthesis and metabolism in myeloproliferative disorders 61
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 61
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials 60
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective 60
Fourth universal definition of myocardial infarction (2018) 60
The coxibs, selective inhibitors of cyclooxygenase-2 58
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 58
Determinants of the interindividual variability in response to antiplatelet drugs. 57
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 56
Prostanoids, aspirin and related compounds 55
The role of aspirin in cancer prevention 54
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 54
Nonsteroidal antiinflammatory drugs: past, present and future 53
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 53
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. 51
Interindividual Variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of the evidence 50
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs 50
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 50
Cigarette smoking knowledge and perceptions among students in four italian medical schools 49
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. 48
Aspirin and Other COX-1 Inhibitors 48
The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis 48
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 47
Diabetes: Does aspirin increase the risk of major bleeds? 46
The P2Y12 receptor: no active metabolite, no party 45
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 44
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 44
Aspirin, 110 years later 42
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets 42
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? 42
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin 42
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development 42
Antiplatelet Therapy 41
Mechanisms, consequences, and prevention of coronary graft failure 39
In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease 38
Selective COX-2 inhibitors: where do we go from here? 37
Aspirin at 120: Retiring, recombining, or repurposing? 37
Knowledge about health effects of cigarette smoking and quitting among Italian university students: the importance of teaching nicotine dependence and treatment in the medical curriculum 36
Measurement of Thromboxane Biosynthesis in Health and Disease 36
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development 35
Nonsteroidal anti-inflammatory drugs and the heart 35
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance" 33
Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer 32
Role of Clinical Pharmacology in the Development of Antiplatelet Drugs 31
Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now 29
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 29
Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation 27
Aspirin and Cancer 27
Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus. Role of interleukin-6 and disease duration. 26
Less Thromboxane, Longer Life 23
Precision antiplatelet therapy 22
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 21
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials 21
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 20
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 20
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs 19
Platelet activation in obese women: role of inflammation and oxidant stress 18
Totale 6.091
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.509
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.509
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020330 0 0 0 0 0 0 37 33 44 47 86 83
2020/2021770 71 83 9 75 104 74 73 23 87 15 124 32
2021/2022787 73 74 12 51 62 21 25 128 38 25 112 166
2022/20231.367 209 189 123 164 146 160 37 93 145 23 51 27
2023/2024797 23 235 35 81 36 53 57 30 14 34 91 108
2024/2025397 34 41 123 51 103 43 2 0 0 0 0 0
Totale 6.162